Skip to main content
Year archive

Cellectis — 2023 filings

All 173 regulatory filings released by Cellectis (ALCLS) in 2023, sourced directly from the official regulator.

173 Filings
2023 Period
2023 filings (173)
Filing Released Lang
FORM 6-K
Foreign Filer Report
2023-12-22 English
Résultats de l’Assemblée Générale Mixte de Cellectis du 22 décembre 2023
AGM Information
2023-12-22 French
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
AGM Information
2023-12-22 English
6-K
Foreign Filer Report
2023-12-22 English
6-K
Foreign Filer Report
2023-12-05 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-05 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2023-12-01 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2023-12-01 English
6-K
Foreign Filer Report
2023-11-17 English
FORM 6-K
Foreign Filer Report
2023-11-17 English
L’Assemblée Générale Extraordinaire de Cellectis se tiendra le 22 décembre 2023
AGM Information
2023-11-17 French
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Report Publication Announcement
2023-11-17 English
6-K
Foreign Filer Report
2023-11-15 English
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
Share Issue/Capital Change
2023-11-15 English
Cellectis Annonce la signature de l’Accord d’Investissement Définitif avec AstraZeneca
Share Issue/Capital Change
2023-11-15 French
SC 13D/A
Major Shareholding Notification
2023-11-13 English
6-K
Foreign Filer Report
2023-11-09 English
FORM 6-K
Foreign Filer Report
2023-11-06 English
6-K
Foreign Filer Report
2023-11-06 English
Cellectis publie ses résultats financiers du troisième trimestre 2023
Earnings Release Q3 2023
2023-11-06 French
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
Earnings Release 9M 2023
2023-11-06 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-11-03 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-11-03 English
FORM 6-K
Foreign Filer Report
2023-11-02 English
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
Regulatory Filings
2023-11-02 English
Cellectis présentera des données préliminaires de l’essai NATHALI_01 et des résultats actualisés de l’essai BALLI_01 lors de la 65ème réunion annuelle de la American Society of Hematology (ASH)
Investor Presentation
2023-11-02 French
FORM 6-K
Foreign Filer Report
2023-11-01 English
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
Earnings Release Q3 2023
2023-11-01 English
Cellectis présentera ses résultats financiers du troisième trimestre 2023 le 6 novembre 2023
Earnings Release 9M 2023
2023-11-01 French
6-K
Foreign Filer Report
2023-11-01 English
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
Capital/Financing Update
2023-11-01 English
Cellectis Annonce une Collaboration Stratégique et un Accord d'Investissement Avec AstraZeneca
M&A Activity
2023-11-01 French
20-F/A
Annual Report FY 2022
2023-10-31 English
6-K
Foreign Filer Report
2023-10-31 English
FORM 6-K
Foreign Filer Report
2023-10-31 English
Cellectis présente des données précliniques sur des cellules « smart » MUC1- CAR T ciblant le cancer du sein triple négatif à l’occasion de la 38ème réunion annuelle de la Society for Immunotherapy of
Regulatory Filings
2023-10-31 French
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Regulatory Filings
2023-10-31 English
FORM 6-K
Foreign Filer Report
2023-10-24 English
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
Regulatory Filings
2023-10-24 English
Cellectis présentera des données précliniques sur son programme de thérapie génique des HSPC ainsi qu’une analyse complète des TALE-BE lors du 30ème Congrès Annuel de l’ESGCT
Regulatory Filings
2023-10-24 French
FORM 6-K
Foreign Filer Report
2023-10-12 English
Cellectis et l'Institut Imagine publient une étude de preuve de concept d'un candidat produit de chirurgie génique pour traiter le syndrome de la phosphoinositide 3-Kinase activée de type 1 (APDS1)
Regulatory Filings
2023-10-12 French
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)
Regulatory Filings
2023-10-12 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-10-03 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-10-03 English
FORM 6-K
Foreign Filer Report
2023-09-27 English
Cellectis présentera des données précliniques sur des cellules « smart » MUC1- CAR T ciblant le cancer du sein triple négatif à l’occasion de la 38ème réunion annuelle de la Society for Immunotherapy
Regulatory Filings
2023-09-27 French
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Regulatory Filings
2023-09-27 English
6-K/A
Foreign Filer Report
2023-09-05 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2023-09-05 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2023-09-05 English
S-8
Registration Form
2023-08-07 English
FORM 6-K
Foreign Filer Report
2023-08-07 English
Cellectis publie le rapport complet des résultats financiers du deuxième trimestre 2023
Interim / Quarterly Report Q2 2023
2023-08-07 French
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
Earnings Release H1 2023
2023-08-07 English
6-K
Foreign Filer Report
2023-08-07 English
FORM 6-K
Foreign Filer Report
2023-08-03 English
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
Earnings Release H1 2023
2023-08-03 English
Cellectis publie ses résultats business et financiers préliminaires du deuxième trimestre 2023
Earnings Release Q2 2023
2023-08-03 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2023-08-01 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2023-08-01 French
FORM 6-K
Foreign Filer Report
2023-07-27 English
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
Earnings Release Q2 2023
2023-07-27 English
Cellectis présentera ses résultats financiers du deuxième trimestre 2023 le 3 août 2023
Report Publication Announcement
2023-07-27 French
FORM 6-K
Foreign Filer Report
2023-07-12 English
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
Board/Management Information
2023-07-12 English
Cellectis nomme le docteur Cécile Chartier, Ph.D. à son conseil d’administration
Board/Management Information
2023-07-12 French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-07-05 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-07-05 English
6-K
Foreign Filer Report
2023-06-29 English
FORM 6-K
Foreign Filer Report
2023-06-28 English
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
AGM Information
2023-06-28 English
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis du 27 juin 2023
AGM Information
2023-06-28 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-06-13 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-06-13 French
FORM 6-K
Foreign Filer Report
2023-06-09 English
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
Regulatory Filings
2023-06-09 English
Cellectis présente des données cliniques et translationnelles actualisées de son essai clinique BALLI-01 à l’European Hematology Association (EHA) 2023
Regulatory Filings
2023-06-09 French
FORM 6-K
Foreign Filer Report
2023-06-05 English
Cellectis a dévoilé des données précliniques à l’occasion d’une présentation orale et deux présentations poster au 29ème congrès annuel de l’International Society for Cell & Gene Therapy (ISCT 2023)
Regulatory Filings
2023-06-05 French
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
Regulatory Filings
2023-06-05 English
SC 13D/A
Major Shareholding Notification
2023-06-01 English
FORM 6-K
Foreign Filer Report
2023-05-31 English
Cellectis publie un article dans Cancer Immunology Research présentant des résultats précliniques de la capacité du produit candidat UCART20x22 à cibler un large spectre de patients atteints de tumeur
Regulatory Filings
2023-05-31 French
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
Regulatory Filings
2023-05-31 English
6-K
Foreign Filer Report
2023-05-22 English
FORM 6-K
Foreign Filer Report
2023-05-17 English
Cellectis présente des données cliniques de l’étude AMELI-01 et des données précliniques sur l’ingénierie multiplex pour une production améliorée de cellules CAR T performantes à l’ASGCT 2023
Regulatory Filings
2023-05-17 French
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
Regulatory Filings
2023-05-17 English
FORM 6-K
Foreign Filer Report
2023-05-12 English
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
Regulatory Filings
2023-05-12 English
Cellectis publie un article dans Frontiers in Immunology dévoilant des données précliniques sur un traitement novateur d’immunothérapie cellulaire CAR T contre les tumeurs solides riches en stroma
Regulatory Filings
2023-05-12 French
FORM 6-K
Foreign Filer Report
2023-05-11 English
Cellectis annonce la présentation d’un poster sur son essai clinique BALLI-01 à l’European Hematology Association (EHA) 2023
Investor Presentation
2023-05-11 French
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
Regulatory Filings
2023-05-11 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-05-10 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-05-10 English
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
Earnings Release Q1 2023
2023-05-04 English
Cellectis publie ses résultats financiers du premier trimestre 2023
Earnings Release Q1 2023
2023-05-04 French
6-K
Foreign Filer Report
2023-05-04 English
FORM 6-K
Foreign Filer Report
2023-05-02 English
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annua
Report Publication Announcement
2023-05-02 English
FORM 6-K
Foreign Filer Report
2023-04-27 English
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
Report Publication Announcement
2023-04-27 English
Cellectis présentera ses résultats financiers du premier trimestre le 4 mai 2023
Earnings Release Q1 2023
2023-04-27 French
FORM 6-K
Foreign Filer Report
2023-04-24 English
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
Legal Proceedings Report
2023-04-24 English
Cellectis implémente CLLS52 pour la première fois en clinique avec l’alemtuzumab de Sanofi
Regulatory Filings
2023-04-24 French
FORM 6-K
Foreign Filer Report
2023-04-17 English
Réunion annuelle de l’American Association for Cancer Research (AACR) : Cellectis présente des données précliniques sur les cellules CAR T MUC1 éditées par TALEN® avec une efficacité améliorée dans le
Investor Presentation
2023-04-17 French
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeti
Regulatory Filings
2023-04-17 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-04-12 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-04-12 English
FORM 6-K
Foreign Filer Report
2023-04-11 English
Cellectis annonce le dosage de son premier patient en Europe avec le produit candidat UCART22 fabriqué en interne
Regulatory Filings
2023-04-11 French
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
Regulatory Filings
2023-04-11 English
6-K
Foreign Filer Report
2023-04-04 English
Cellectis a conclu le contrat de souscription de bons de souscription d’actions avec la Banque Européenne d'Investissement et annonce le tirage de la première tranche de 20 millions d’euros
Capital/Financing Update
2023-04-04 French
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
Capital/Financing Update
2023-04-04 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-03-15 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2023-03-15 English
FORM 6-K
Foreign Filer Report
2023-03-14 English
Cellectis présentera un poster sur les cellules CAR T MUC1 éditées par TALEN® ciblant le cancer du sein triple négatif à la réunion annuelle de l'American Association of Cancer Research (AACR)
Regulatory Filings
2023-03-14 French
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Regulatory Filings
2023-03-14 English
20-F
Annual Report FY 2022
2023-03-14 English
FORM 6-K
Foreign Filer Report
2023-03-08 English
Cellectis publie ses résultats financiers du quatrième trimestre 2022 et de l’exercice 2022
Earnings Release FY 2022
2023-03-08 French
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Earnings Release Q4 2022
2023-03-08 English
FORM 6-K
Foreign Filer Report
2023-03-06 English
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
Earnings Release Q4 2022
2023-03-06 French
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
Earnings Release Q4 2022
2023-03-06 English
FORM 6-K
Foreign Filer Report
2023-03-01 English
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
Report Publication Announcement
2023-03-01 English
Cellectis présentera ses résultats financiers du quatrième trimestre et de l’année 2022 le 8 mars 2023
Earnings Release Q4 2022
2023-03-01 French
SC 13G/A
Major Shareholding Notification
2023-02-14 English
SC 13D/A
Major Shareholding Notification
2023-02-14 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-02-09 French
Monthly information on share capital and company voting rights
Regulatory Filings
2023-02-09 English
6-K
Foreign Filer Report
2023-02-08 English
FORM 6-K
Foreign Filer Report
2023-02-08 English
Cellectis annonce le règlement livraison de son offre d’ADS et l’exercice de l’option de surallocation des banques garantes
Share Issue/Capital Change
2023-02-08 French
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
Capital/Financing Update
2023-02-08 English
6-K
Foreign Filer Report
2023-02-07 English
424B5
Prospectus
2023-02-03 English
FORM 6-K
Foreign Filer Report
2023-02-03 English
Cellectis complète l’annonce des modalités définitives de son offre d’ADS avec la répartition de son capital après la réalisation de son offre d’ADS
Capital/Financing Update
2023-02-03 French
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
Share Issue/Capital Change
2023-02-03 English
FORM 6-K
Foreign Filer Report
2023-02-03 English
Cellectis annonce les modalités définitives de son offre d’ADS
Capital/Financing Update
2023-02-03 French
Cellectis Announces Pricing of Follow-On Offering
Share Issue/Capital Change
2023-02-03 English
FORM 6-K
Foreign Filer Report
2023-02-02 English
424B5
Prospectus
2023-02-02 English
Cellectis annonce le lancement d’une nouvelle offre d’ADS
Share Issue/Capital Change
2023-02-02 French
Cellectis Announces Launch of Follow-On Offering
Share Issue/Capital Change
2023-02-02 English
FORM 6-K
Foreign Filer Report
2023-01-20 English
Cellectis modifie sa note convertible de 20 millions de dollars dans le cadre de l’accord de collaboration avec son partenaire Cytovia Therapeutics
Capital/Financing Update
2023-01-20 French
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Capital/Financing Update
2023-01-20 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-01-18 English
SC 13D/A
Major Shareholding Notification
2023-01-17 English
6-K
Foreign Filer Report
2023-01-17 English
FORM 6-K
Foreign Filer Report
2023-01-17 English
Calyxt et Cibus annoncent la signature d’un Accord de Fusion
M&A Activity
2023-01-17 French
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
M&A Activity
2023-01-17 English
Monthly information on share capital and company voting rights
Regulatory Filings
2023-01-09 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2023-01-09 French
FWP
Regulatory Filings
2023-01-04 English
FORM 6-K
Foreign Filer Report
2023-01-04 English
Cellectis met en place un programme At the Market sur le Nasdaq
Share Issue/Capital Change
2023-01-04 French
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Share Issue/Capital Change
2023-01-04 English
6-K
Foreign Filer Report
2023-01-04 English
424B5
Prospectus
2023-01-04 English
6-K
Foreign Filer Report
2023-01-04 English
6-K
Foreign Filer Report
2023-01-04 English